Nasdaq grants CURX additional 180 days until Nov 2, 2026 to meet $1 bid price

Curanex Pharmaceuticals Inc

Received Nasdaq notice on Nov 5, 2025 for bid price below $1.00; initial 180-day period ended May 4, 2026.
Nasdaq granted second 180-day compliance period through Nov 2, 2026, based on meeting other listing requirements.
Company may implement a reverse stock split to cure the deficiency.
If bid price stays at $1.00 for 10 consecutive days during extension, compliance will be confirmed.
Failure to regain compliance by Nov 2, 2026 could result in delisting, with appeal rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.